Microdosing Retatrutide: What Low Doses Actually Did in the Trials

Microdosing retatrutide has no official definition. Online it usually means taking far less than the trial doses, around 0.25 mg to 1 mg a week, or splitting a normal weekly amount into several small shots. No trial has tested either approach. The closest evidence comes from fixed low doses in Phase 2. A steady 0.5 mg a week didn't beat placebo on blood sugar or weight, and 1 mg a week took off 8.7% of body weight over 48 weeks, roughly a third of what 12 mg did.

So the honest answer to "can you micro dose reta" is that people do it and the data on it is thin. The low-dose results published so far fit in one table, below.

What microdosing retatrutide means on forums

The word covers two ideas, and forum posts mix them up. Anything people write about either one is a user report, not a study, and we've left forum anecdotes out of the numbers on this page.

The first idea is a low weekly total: staying at 0.25 mg, 0.5 mg or 1 mg for weeks or months, or climbing much more slowly than the trials did. The second is a split: the same weekly amount as two, three or seven smaller shots.

Neither matches anything Lilly has tested. In every Phase 3 trial reported so far, people started at 2 mg once a week and stepped up every 4 weeks to a target of 4, 9 or 12 mg, according to Lilly's trial releases. Retatrutide is still investigational, and no approved version exists yet. Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026.

What doses under 4 mg did in the trials

Low doses have been given to people, just never as a microdosing plan. Each group below stayed on one fixed dose, or climbed to it, for the whole study. The 4 mg row is for scale.

The Phase 2 nausea figures come from the ClinicalTrials.gov results tables and count anyone who reported it at least once over the whole study. The 0.5 mg row is the clearest signal on the page: in 47 people with type 2 diabetes, that dose was easy to tolerate and barely did anything, though 37% reached an HbA1c under 7.0% by week 36, against 22% on placebo.

Does a reta microdose work for weight loss?

At 1 mg, yes, a little. At 0.5 mg, the diabetes trial saw no more weight loss than placebo. The Phase 2 obesity trial is the only one that tested 1 mg for weight, and its dose curve rises steeply at first and then flattens.

The curve shows why microdosing appeals. Going from 1 mg to 4 mg quadruples the dose and roughly doubles the weight loss, and going to 12 mg multiplies the dose by 12 and the weight loss by a little under 3. Per milligram, the smallest dose looks like the best deal, which matters to people paying per vial.

Per person, it looks different. By week 48, about 1 in 6 people (16%) on 1 mg had lost 15% or more of their body weight, against 83% on 12 mg, according to the trial's ClinicalTrials.gov results.

Our read: 1 mg is a real dose, with a real effect on weight and liver fat, but much smaller than at 4 mg and up. Anyone microdosing for trial-sized results will likely be disappointed.

A common question is whether a microdose still raises fat burning. In the Nature Medicine fatty liver substudy, beta-hydroxybutyrate, a blood marker of fat burning, rose 2 to 3 fold in a dose-related pattern, and the paper reports that rise at 4 mg and higher. No published data covers 0.5 mg or a split dose. The same substudy found 1 mg cut liver fat by 42.9% at 24 weeks, so the low end did more than nothing.

What the lower Phase 3 doses did

The Phase 3 trials did test lower doses, as target doses. The lowest was 4 mg, reached by one 4-week step at 2 mg, and it did far more than the Phase 2 1 mg group.

In TRIUMPH-1, 4 mg took off 19.0% of body weight over 80 weeks, against 28.3% on 12 mg (efficacy estimand). The NEJM paper's treatment-regimen figures are 17.6% and 25.0%. Nausea was 28.6% on 4 mg and 42.4% on 12 mg, against 14.8% on placebo. Stopping for side effects was 4.1% on 4 mg, 6.9% on 9 mg and 11.3% on 12 mg, against 4.9% on placebo. That compares different trials, people and lengths, so it isn't a 1 mg versus 4 mg test.

The pattern isn't the same in every trial. In TRIUMPH-2, 11.6% on 9 mg stopped for side effects, more than the 7.7% on 12 mg. In TRANSCEND-T2D-1, in people with type 2 diabetes, 4 mg lowered A1C by 1.7 points and weight by 11.5% over 40 weeks (efficacy estimand).

Can a smaller dose cut the side effects?

Smaller doses did cause less nausea in Phase 2, and they also did less. The trials tested another way to ease side effects: starting lower and climbing more slowly toward the same target.

Both Phase 2 trials compared a 2 mg start with a 4 mg start. In the type 2 diabetes trial published in The Lancet, the group that reached 8 mg from a 2 mg start reported nausea in 26.9% (7 of 26), against 41.7% (10 of 24) for the group that started at 4 mg. Weight loss at 36 weeks was 16.81% and 16.34%, so the gentler climb gave up nothing. In the obesity trial the gap was bigger: 17.1% nausea on the slow path to 8 mg, 60.0% on the fast one. The retatrutide starting dose page covers the 2 mg start in detail.

The Phase 3 data points the same way. In TRANSCEND-T2D-1, Lilly reported that nausea, diarrhea and vomiting came mainly during dose escalation. The retatrutide nausea page covers what helps and how long it lasts.

Splitting the weekly amount is a separate question. Lilly Medical Information puts time to peak at 12 to 72 hours after a dose and the half-life at about 6 days, which the retatrutide half-life page explains. On that half-life, two 6 mg shots 3.5 days apart keep the average level the same as one 12 mg shot and trim the peak by roughly 17% (our arithmetic). Whether a lower peak means less nausea is unknown. The how often to take retatrutide page works through that math for each split schedule.

How approved drugs handle a dose you can't tolerate

Approved drugs in the same class don't use microdoses either. Their labels answer side effects with a slower climb or a lower maintenance dose. This is class evidence from tirzepatide and semaglutide, not retatrutide data.

Neither label has a dose below its starting dose, and neither splits the weekly shot. If side effects make you want to go lower, the retatrutide side effects page covers what's normal during a step up and what isn't.

The syringe and vial problems with tiny doses

Small doses mean small volumes, and small volumes leave less room for error. Most microdosing talk online assumes a vial of powder mixed with water at home, so the dose depends on your own arithmetic.

At that mix, 2 mg is 40 units, 0.5 mg is 10 units and 0.25 mg is 5 units. Misread the syringe by a single unit and you've changed a 2 mg dose by 2.5%, a 0.5 mg dose by 10% and a 0.25 mg dose by 20%. That's our arithmetic. Try your own vial below, or use the full retatrutide calculator. The retatrutide units page has the conversion chart.

The vial also lasts much longer. A 10 mg vial covers 20 weeks at 0.5 mg a week. Nobody has published how long mixed retatrutide stays stable, because no approved product exists. The how to reconstitute retatrutide page covers mixing and handling, and the reconstitution calculator sets the water volume.

Then there's what's in the vial. Lilly's October 28, 2026 release says retatrutide "cannot be legally sold or marketed for human use" and "Anyone purporting to sell retatrutide to consumers is breaking the law," so nothing sold online is Lilly's product (see is retatrutide legal). When Australia's TGA tested a vial sold as retatrutide after a serious adverse event report, it held no retatrutide at all, only undeclared semaglutide at about 8 times the level in approved products. Victoria's health department linked 6 cases of acute liver injury since January 2026 to products labeled Retatrutide, possibly from a contaminant. A careful 0.5 mg draw means little if the label is wrong. If you're weighing retatrutide for sale anyway, that page explains batch-specific test reports and the red flags to check before trusting any label.

What nobody has tested yet

Nobody has published a trial of a retatrutide microdose ladder, a split weekly dose, or months on 1 mg or less. The low-dose numbers above come from 9 to 69 people per group, and each low dose was the bottom of a range being compared, not a plan tested alone.

Two Lilly trials will add something. As listed on ClinicalTrials.gov on October 31, 2026, TRIUMPH-9 compares 3 dose-escalation schemes in about 600 people without type 2 diabetes, with weight change at week 104 as the main result; primary completion is estimated for October 2028. TRIUMPH-6 (an estimated 643 people) gives everyone 80 weeks on one dose, then randomizes them to stay on it, move to a second dose, or move to placebo for 36 more weeks. The registry doesn't name either dose, so a step down isn't confirmed. Primary completion is estimated for April 2028.

Until then, the tested path is the one in the trials: 2 mg to start, a step every 4 weeks, and a target of 4, 9 or 12 mg. If you're thinking about a lower dose, take the table above to a doctor, along with any other drugs you use.